- CRDF Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
CORRESP Filing
Cardiff Oncology (CRDF) CORRESPCorrespondence with SEC
Filed: 17 Nov 17, 12:00am
Sheppard, Mullin, Richter & Hampton LLP
30 Rockefeller Plaza
New York, NY 10112
November 17, 2017
Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549-4720
Attention: Christine Westbrook
Re: | Trovagene, Inc. |
Registration Statement onForm S-1 |
Filed October 25, 2017 |
FileNo. 333-221115 |
Dear Ms. Westbrook:
This letter sets forth the responses of Trovagene, Inc., a Delaware corporation (the “Company” or “we”), to the comments received from the Staff of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange Commission (the “Commission”) on November 7, 2017 concerning the Company’s registration statement onForm S-1.
FormS-1 filed 10/25/2017
Cover Page
1. | It appears that shares of common stock and warrants will be offered and priced together as a unit. Please amend your registration statement to add units or tell us why such disclosure is not required. Please also revise your cover page disclosure to include the method by which the price of the securities is to be determined. Refer to Instruction 2 to Item 501(b)(3) of RegulationS-K. |
Amendment No. 1 to Form S-1 has been modified to add units. In addition, we have added disclosure to the front cover page of the prospectus describing the method by which the price of the securities will be determined.
2. | We note your disclosure on page 38 that H.C. Wainwright & Co., LLC will use its reasonable best efforts to arrange for the sale of the securities offered by the prospectus. Please also revise the cover page to include all of the information required by Item 501(b)(8) of RegulationS-K. |
We have revised the front cover page of the prospectus in Amendment No. 1 to FormS-1 to include the information required by Item 501(b)(8) of RegulationS-K.
Sincerely,
/s/ Jeffrey J. Fessler
Jeffrey J. Fessler